Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

New guidance on stem cell therapies
Stem cell medicines are produced in large batches which need to be sterile.
Document addresses concerns raised on sterility 

The first ever guidance for stem cell-based therapies in animals has been-been published by the European Medicines Agency (EMA).

The guidance follows a review of scientific evidence by the Committee for Medicinal Products for Veterinary Use (CVMP), which identified the sterility of stem-cell therapies as a ‘priority area’.

Taking the form of a question and answer document, the guidance addresses eight main concerns raised by manufacturers and authorities with regards to ensuring sterile and safe stem cell-based therapies.

Veterinary stem cell medicines originate from tissues from a donor from the same species of animal. They are produced in large batches which need to be sterile as they are administered by injection into the body.

Contamination can occur at various stages - from the initial sampling of cells and tissues, up to the final packaging into vials, syringes or bottles. The EMA states that the most critical step is the sourcing and collection of the stem cells as it is not always possible to put in place aseptic techniques at this stage.

Up to now, there has been no specific guidance from the EMA on how stem cell-based veterinary medicine should be used. Guidance documents have been produced for human cell-based products or for general requirements on animal cell-based products in the USA.

In recent years, interest and research into new therapies such as stem cell or gene therapy has gathered speed. In 2014, the EMA established an Ad Hoc expert group of veterinary novel therapies to provide general guidance on the requirements of novel veterinary medicines.

The EMA defines novel therapies as therapies that are entirely new to the veterinary sector. This is because they are genuinely new and have not been used in animals before, or new only to the veterinary sphere, but well known in human medicine.

 

 

 

Become a member or log in to add this story to your CPD history

SPVS and FIVP launch VSA survey

News Story 1
 SPVS and FIVP have collaborated to launch a short survey about the proposed reform of the Veterinary Surgeons Act.

The survey will ensure that each organisation's submission accurately represents the experiences of practising veterinary professionals. It will also explore awareness, use and perceived value of the roles undertaken by the RCVS.

It takes around 5-10 minutes to complete, and all responses are anonymous. The survey can be completed here until Thursday, 19 March 2026. 

Click here for more...
News Shorts
RCVS annual renewal fee for vets due

RCVS' annual renewal fee for veterinary surgeons is now due. Vets must pay their renewal fee before Wednesday, 1 April 2026.

This year's standard annual fee has increased to 431 from last year's 418. This is an approximately three per cent increase, as approved by RCVS Council and the Privy Council.

Tshidi Gardner, RCVS treasurer, said: "The small fee increase will be used to help deliver both our everyday activities and our new ambitious Strategic Plan, which includes aims such as achieving new legislation, reviewing the Codes of Professional Conduct and supporting guidance, and continuing to support the professions through activities such as the Mind Matters Initiative, RCVS Academy and career development."

A full breakdown of the new fees is on the RCVS website. Information about tax relief is available on the UK government website.